NDC-11 (Package) | NDC-9 (Product) (Descending) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72603-0104-01 | 72603-0104 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | May 10, 2019 | In Use | |
72603-0103-01 | 72603-0103 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 29, 2019 | In Use | |
72603-0101-01 | 72603-0101 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 17, 2019 | In Use | |
72579-0011-01 | 72579-0011 | Zanubrutinib | BRUKINSA | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Nov. 14, 2019 | Sept. 30, 2021 | In Use |
72579-0011-02 | 72579-0011 | Zanubrutinib | BRUKINSA | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Nov. 14, 2019 | In Use | |
72578-0019-06 | 72578-0019 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 15, 2019 | In Use | |
72578-0019-16 | 72578-0019 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 15, 2019 | In Use | |
72572-0520-25 | 72572-0520 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 18, 2019 | In Use | |
72572-0122-25 | 72572-0122 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 10.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Nov. 13, 2019 | In Use | |
72493-0103-03 | 72493-0103 | Mitomycin | JELMYTO | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Instillation | May 1, 2020 | In Use | ||
72485-0223-20 | 72485-0223 | Gemcitabine Hydrochloride | Gemcitabine | 2.0 g/52.6mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 15, 2020 | In Use | |
72485-0222-10 | 72485-0222 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 1.0 g/26.3mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 15, 2020 | In Use | |
72485-0221-02 | 72485-0221 | Gemcitabine Hydrochloride | Gemcitabine | 200.0 mg/5.26mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 15, 2020 | In Use | |
72485-0219-30 | 72485-0219 | Erlotinib hydrochloride | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 6, 2019 | In Use | |
72485-0218-30 | 72485-0218 | Erlotinib hydrochloride | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 6, 2019 | In Use | |
72485-0217-30 | 72485-0217 | Erlotinib hydrochloride | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 6, 2019 | In Use | |
72485-0216-08 | 72485-0216 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 15, 2020 | In Use | |
72485-0215-04 | 72485-0215 | Docetaxel | Docetaxel | 80.0 mg/4mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 15, 2020 | In Use | |
72485-0214-01 | 72485-0214 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 15, 2020 | In Use | |
72485-0213-15 | 72485-0213 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sept. 4, 2020 | In Use | |
72485-0212-05 | 72485-0212 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 1, 2019 | In Use | |
72485-0211-02 | 72485-0211 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 1, 2019 | In Use | |
72485-0210-08 | 72485-0210 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | June 1, 2019 | In Use | |
72485-0205-12 | 72485-0205 | Capecitabine | Capecitabine 500mg | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 1, 2019 | In Use | |
72485-0204-60 | 72485-0204 | Capecitabine | Capecitabine 150mg | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 1, 2019 | In Use |
Found 10,000 results in 4 milliseconds — Export these results